Cette recherche s'applique uniquement aux ressources en bibliothèque.
227 résultats
Trier par:
Ajouter à la liste:
Étendre à toutes les références (sans texte intégral)
    • Plusieurs versions

    Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?

    Reinmuth, Niels, Schuler, Martin
    European journal of cancer (Oxford, England : 1990), March 2021, Vol.145, pp.255-257 [Revue évaluée par les pairs]

    • Article
    Sélectionner

    Impact of EBUS-TBNA in addition to FFDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC

    Guberina, Maja, Darwiche, Kaid, Hautzel, Hubertus, Ploenes, Till, Pöttgen, Christoph, Guberina, Nika, Herrmann, Ken, Umutlu, Lale, Wetter, Axel, Theegarten, Dirk, Aigner, Clemens, Eberhardt, Wilfried Ernst Erich, Schuler, Martin, Karpf-Wissel, Rüdiger, Stuschke, Martin
    European journal of nuclear medicine and molecular imaging, 05 February 2021 [Revue évaluée par les pairs]
    MEDLINE/PubMed (U.S. National Library of Medicine)
    Disponible
    Plus…
    Titre: Impact of EBUS-TBNA in addition to FFDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
    Auteur: Guberina, Maja; Darwiche, Kaid; Hautzel, Hubertus; Ploenes, Till; Pöttgen, Christoph; Guberina, Nika; Herrmann, Ken; Umutlu, Lale; Wetter, Axel; Theegarten, Dirk; Aigner, Clemens; Eberhardt, Wilfried Ernst Erich; Schuler, Martin; Karpf-Wissel, Rüdiger; Stuschke, Martin
    Sujet: Ebus-Tbna ; Non-Small Cell Lung Cancer (Nsclc) ; Radiation ; Radiotherapy ; Stage III ; Target Volume Definition ; [18f]Fdg-Pet/CT
    Description: PURPOSE/INTRODUCTION: [F]FDG-PET/CT is the standard imaging-technique for radiation treatment (RT) planning in locally advanced non-small cell lung cancer (NSCLC). The purpose of this study was to examine the additional value of endobronchial-ultrasound transbronchial needle aspiration (EBUS-TBNA) to standard PET/CT for mediastinal lymph-node (LN) staging and its impact on clinical target volume (CTV). All consecutive patients with primary stage III NSCLC who underwent [F]FDG-PET/CT and EBUS-TBNA prior to RT were analyzed from 12/2011 to 06/2018. LN-stations were assessed by an expert-radiologist and a nuclear medicine-physician. CTV was evaluated by two independent radiation oncologists. LNs were grouped with increasing distance along the lymphatic chains from primary tumor into echelon-1 (ipsilateral hilum), echelon-2 (LN-station 7 and ipsilateral 4), and echelon-3 (remaining mediastinum and contralateral hilum). A total of 675 LN-stations of which 291 were positive for tumor-cells, were sampled by EBUS-TBNA in 180 patients. The rate of EBUS-positive LNs was 43% among all sampled LNs. EBUS-positivity in EBUS-probed LNs decreased from 85.8% in echelon-1 LNs to 42.4%/ 9.6% in echelon-2/ -3 LNs, respectively (p < 0.0001, Fisher's exact test). The false discovery rate of PET in comparison with EBUS results rose from 5.3% in echelon-1 to 32.9%/ 69.1% in echelon-2/ -3 LNs, respectively (p < 0.0001, Fisher's exact test). Sensitivity and specificity of FDG-PET/CT ranged from 85 to 99% and 67 to 80% for the different echelons. In 22.2% patients, EBUS-TBNA finding triggered changes of the treated CTV, compared with contouring algorithms based on FDG-avidity as the sole criterion for inclusion. CTV was enlarged in 6.7% patients due to EBUS-positivity in PET-negative LN-station and reduced in 15.5% by exclusion of an EBUS-negative but PET-positive LN-station. The false discovery rate of [F]FDG-PET/CT increased markedly with distance from the primary tumor. Inclusion of systematic mediastinal LN mapping by EBUS-TBNA in addition to PET/CT has the potential to increase accuracy of target volume definition, particularly in echelon-3 LNs. EBUS-TBNA is recommended as integral part of staging for radiochemotherapy in stage III NSCLC.
    Fait partie de: European journal of nuclear medicine and molecular imaging, 05 February 2021
    Identifiant: 1619-7089 (E-ISSN); 33547554 Version (PMID); 10.1007/s00259-021-05204-7 (DOI)

    • Plusieurs versions

    Assessment of coronary artery disease during hospitalization for cancer treatment

    Mrotzek, Simone M, Lena, Alessia, Hadzibegovic, Sara, Ludwig, Ria, Al-Rashid, Fadi, Mahabadi, Amir A, Mincu, Raluca I, Michel, Lars, Johannsen, Laura, Hinrichs, Lena, Schuler, Martin, Keller, Ulrich, Anker, Stefan D, Landmesser, Ulf, Rassaf, Tienush, Anker, Markus S, Totzeck, Matthias
    Clinical research in cardiology : official journal of the German Cardiac Society, February 2021, Vol.110(2), pp.200-210 [Revue évaluée par les pairs]

    • Plusieurs versions

    Bile formation in long-term ex situ perfused livers

    Eshmuminov, Dilmurodjon, Schuler, Martin J, Becker, Dustin, Bautista Borrego, Lucia, Mueller, Matteo, Hagedorn, Catherine, Häusler, Stephanie, Steiger, Julia, Tibbitt, Mark W, Dutkowski, Philipp, Rudolf Von Rohr, Philipp, Stieger, Bruno, Hefti, Max, Clavien, Pierre-Alain
    Surgery, 06 January 2021 [Revue évaluée par les pairs]

    • Article
    Sélectionner

    Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations

    Metzenmacher, Martin, Goetz, Moritz, Herold, Thomas, Stuschke, Martin, Aigner, Clemens, Darwiche, Kaid, Eberhardt, Wilfried E, Schuler, Martin, Wiesweg, Marcel
    Clinical lung cancer, 02 December 2020 [Revue évaluée par les pairs]
    MEDLINE/PubMed (U.S. National Library of Medicine)
    Disponible
    Plus…
    Titre: Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations
    Auteur: Metzenmacher, Martin; Goetz, Moritz; Herold, Thomas; Stuschke, Martin; Aigner, Clemens; Darwiche, Kaid; Eberhardt, Wilfried E; Schuler, Martin; Wiesweg, Marcel
    Sujet: Braf V600e Mutation ; Personalized Medicine ; Resistant Pathways ; Squamous Nsclc ; Targeted Therapy
    Fait partie de: Clinical lung cancer, 02 December 2020
    Identifiant: 1938-0690 (E-ISSN); 33551244 Version (PMID); 10.1016/j.cllc.2020.11.008 (DOI)

    • Plusieurs versions

    Hyperoxia in portal vein causes enhanced vasoconstriction in arterial vascular bed

    Eshmuminov, Dilmurodjon, Becker, Dustin, Hefti, Max L, Mueller, Matteo, Hagedorn, Catherine, Dutkowski, Philipp, Rudolf Von Rohr, Philipp, Halbe, Maximilian, Segerer, Stephan, Tibbitt, Mark W, Bautista Borrego, Lucia, Schuler, Martin J, Clavien, Pierre-Alain
    Scientific reports, 01 December 2020, Vol.10(1), pp.20966 [Revue évaluée par les pairs]

    • Plusieurs versions

    Label-free vibrational imaging of different Aβ plaque types in Alzheimer’s disease reveals sequential events in plaque development

    Röhr, Dominik, Boon, Baayla D. C., Schuler, Martin, Kremer, Kristin, Hoozemans, Jeroen J. M., Bouwman, Femke H., el-Mashtoly, Samir F., Nabers, Andreas, Großerueschkamp, Frederik, Rozemuller, Annemieke J. M., Gerwert, Klaus
    Acta neuropathologica communications, 2020, Vol.8(1), pp.urn:issn:2051-5960 [Revue évaluée par les pairs]

    • Plusieurs versions

    Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial

    Kasper, Stefan, Meiler, Johannes, Knipp, Heike, Höhler, Thomas, Reimer, Peter, Steinmetz, Tilman, Berger, Winfried, Linden, Gabriele, Reis, Henning, Markus, Peter, Paul, Andreas, Dechêne, Alexander, Schumacher, Brigitte, Kostbade, Karina, Virchow, Isabel, Ting, Saskia, Worm, Karl, Schmid
    Clinical colorectal cancer, December 2020, Vol.19(4), pp.236-247.e6 [Revue évaluée par les pairs]

    • Plusieurs versions

    Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis

    Nothdurft, Silke, Thumser-Henner, Clotilde, Breitenbücher, Frank, Okimoto, Ross A, Dorsch, Madeleine, Opitz, Christiane A, Sadik, Ahmed, Esser, Charlotte, Hölzel, Michael, Asthana, Saurabh, Forster, Jan, Beisser, Daniela, Kalmbach, Sophie, Grüner, Barbara M, Bivona, Trever G, Schramm, Alexander, Schuler
    Oncogenesis, 19 November 2020, Vol.9(11), pp.102 [Revue évaluée par les pairs]

    • Plusieurs versions

    ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer

    Reissig, Timm M, Sara, Linda, Ting, Saskia, Reis, Henning, Metzenmacher, Martin, Eberhardt, Wilfried E E, Zaun, Gregor, Herold, Thomas, Aigner, Clemens, Darwiche, Kaid, Stuschke, Martin, Schildhaus, Hans-Ulrich, Schuler, Martin, Wiesweg, Marcel
    Lung cancer (Amsterdam, Netherlands), November 2020, Vol.149, pp.10-16 [Revue évaluée par les pairs]